A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

NCT02495233 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated due to adverse events related to the combination therapy

Conditions

Interventions

Sponsor

Astellas Pharma Global Development, Inc.